MonarchE 4-year: abemaciclib + endocrine therapy for HR+, HER2-, node-positive, high-risk early BC скачать в хорошем качестве

MonarchE 4-year: abemaciclib + endocrine therapy for HR+, HER2-, node-positive, high-risk early BC

Hope Rugo, MD, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, provides an overview of the results from a pre-planned overall-survival (OS) interim analysis, including 4-year efficacy outcomes of the Phase III monarchE (NCT03155997) trial investigating abemaciclib plus endocrine therapy for HR-positive, HER2-negative, node-positive, high-risk early breast cancer. Previous results from the monarchE trial demonstrated a significant and clinically meaningful improvement in invasive disease-free survival (IDFS) and distant relapse-free survival (DRFS). In the intention-to-treat (ITT) population, at 4 years, IDFS rates had improved from 79.4% to 85.8% (absolute difference 6.4%), and in DRFS rates from 82.5% to 88.4% (absolute difference 5.9%). The continued separation of the curves was associated with an increase in absolute benefit in IDFS 4-year rates compared to 2-and 3-year IDFS rates (absolute difference 2.8% and 4.8% respectively). While OS remained immature, there was a lower number of deaths observed in the abemaciclib plus endocrine therapy arm compared to the endocrine therapy alone arm. This interview took place at the San Antonio Breast Cancer Symposium (SABCS) 2022 in San Antonio, TX. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.